toyocamycin has been researched along with Cancer of Prostate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Andolfi, C; Culig, Z; De Wulf, P; Gruber, M; Handle, F; Haybaeck, J; Klocker, H; Puhr, M; Schäfer, G | 1 |
| Ahn, SC; Choi, HD; Kim, KY; Kim, SH; Kim, YW; Nam, HW; Park, SG; Seo, YK; Yu, SN | 1 |
| Cho, YH; Kim, MK; Lee, CH; Moon, SI; Park, HY | 1 |
3 other study(ies) available for toyocamycin and Cancer of Prostate
| Article | Year |
|---|---|
The Oncogenic Protein Kinase/ATPase RIOK1 Is Up-Regulated via the c-myc/E2F Transcription Factor Axis in Prostate Cancer.
Topics: Adenosine Triphosphatases; Cell Line, Tumor; Cell Proliferation; E2F Transcription Factors; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Male; Prostatic Neoplasms; Protein Kinases; Toyocamycin | 2023 |
Toyocamycin induces apoptosis via the crosstalk between reactive oxygen species and p38/ERK MAPKs signaling pathway in human prostate cancer PC-3 cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Humans; Male; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Reactive Oxygen Species; Toyocamycin | 2017 |
Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Humans; Male; Phosphorylation; Prostatic Neoplasms; Serine; Signal Transduction; Toyocamycin; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2006 |